Plain-English translation of NCT06529250 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether intermediate-dose regimen works better than the standard chemotherapy approach (called 3+7) for people with a particular genetic form of acute myeloid leukemia (AML). About 148 patients will be randomly assigned to receive one of the two treatments. The goal is to see which treatment helps more patients reach complete remission (where cancer cells can no longer be detected).
Acute myeloid leukemia is a serious blood cancer, and for patients with this specific genetic mutation, doctors want to know if a newer chemotherapy approach might work better than the standard treatment that has been used for many years.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive chemotherapy as an inpatient over several weeks. You'll be randomly assigned to receive one of two chemotherapy approaches. If your cancer goes into remission, you'll receive additional high-dose chemotherapy courses. If your cancer doesn't respond initially, you may receive a second round of different chemotherapy drugs. Throughout treatment, you'll have regular blood tests and imaging to monitor your response and check for any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China